Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.

S.W. Lam; S.M. de Groot; A.H. Honkoop; A. Jager; A.J. ten Tije; M.M.E.M. Bos; S.C. Linn; J. van den Bosch; J.R. Kroep; J.J. Braun; H. van Tinteren; x. Dutch Breast Cancer Research Group; E. Boven

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.

Translated title of the contribution: Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.

S.W. Lam
, S.M. de Groot
, A.H. Honkoop
, A. Jager
, A.J. ten Tije
, M.M.E.M. Bos
, S.C. Linn
, J. van den Bosch
, J.R. Kroep
, J.J. Braun
, H. van Tinteren
, x. Dutch Breast Cancer Research Group
, E. Boven

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.
Original language	Undefined/Unknown
Pages (from-to)	3077-3088
Number of pages	12
Journal	European Journal of Cancer
Volume	50
Issue number	18
Publication status	Published - 2014

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/25459393

Cite this

Lam, S. W., de Groot, S. M., Honkoop, A. H., Jager, A., ten Tije, A. J., Bos, M. M. E. M., Linn, S. C., van den Bosch, J., Kroep, J. R., Braun, J. J., van Tinteren, H., Dutch Breast Cancer Research Group, X., & Boven, E. (2014). Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. European Journal of Cancer, 50(18), 3077-3088. http://www.ncbi.nlm.nih.gov/pubmed/25459393

@article{d8344e4999134f6b9d48bf4e66eeed61,

title = "Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.",

author = "S.W. Lam and \{de Groot\}, S.M. and A.H. Honkoop and A. Jager and \{ten Tije\}, A.J. and M.M.E.M. Bos and S.C. Linn and \{van den Bosch\}, J. and J.R. Kroep and J.J. Braun and \{van Tinteren\}, H. and \{Dutch Breast Cancer Research Group\}, x. and E. Boven",

year = "2014",

language = "Undefined/Unknown",

volume = "50",

pages = "3077--3088",

number = "18",

}

Lam, SW, de Groot, SM, Honkoop, AH, Jager, A, ten Tije, AJ, Bos, MMEM, Linn, SC, van den Bosch, J, Kroep, JR, Braun, JJ, van Tinteren, H, Dutch Breast Cancer Research Group, X & Boven, E 2014, 'Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.', European Journal of Cancer, vol. 50, no. 18, pp. 3077-3088. <http://www.ncbi.nlm.nih.gov/pubmed/25459393>

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. / Lam, S.W.; de Groot, S.M.; Honkoop, A.H. et al.
In: European Journal of Cancer, Vol. 50, No. 18, 2014, p. 3077-3088.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial.

AU - Lam, S.W.

AU - de Groot, S.M.

AU - Honkoop, A.H.

AU - Jager, A.

AU - ten Tije, A.J.

AU - Bos, M.M.E.M.

AU - Linn, S.C.

AU - van den Bosch, J.

AU - Kroep, J.R.

AU - Braun, J.J.

AU - van Tinteren, H.

AU - Dutch Breast Cancer Research Group, x.

AU - Boven, E.

PY - 2014

Y1 - 2014

M3 - Article

SN - 0959-8049

VL - 50

SP - 3077

EP - 3088

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 18

ER -